Found 10 articles
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST.
COVAXX Announces Early Design and Testing of New Vaccine Candidate to Address Mutations in SARS-CoV-2
New York, New York--(Newsfile Corp. - January 8, 2021) - COVAXX, a U.S. company developing a multitope, peptide-based vaccine to fight COVID-19, announced today that the company has initiated preclinical work on a second vaccine candidate to address the latest mutations of the SARS-CoV-2 responsible for COVID-19, and specifically the South African mutation.
Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo's existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX t
Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets Expected to support up to 480 million doses of UB-612 for India and other countries Agreement leverages Aurobindo Pharma’s existing development, commercial and manufacturing infrastructure
COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries
COVAXX, a U.S. company developing a multitope peptide-based vaccine to fight COVID-19, announces advanced purchase commitments of more than 140 million doses of its UB-612 vaccine, totaling over $2.8 billion, to deliver vaccines in multiple countries, including Brazil, Ecuador and Peru.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
- First Healthy Adult Volunteers Safely Dosed with UB-612 - Clinical Trial Currently Enrolling up to 60 Healthy Volunteers - Taiwan's Ministry of Health and Welfare Approves Up to $15M (USD) Grant to Support Phase 1 and 2 of Human Trials - Clinical Trial Expands on Existing International Collaborations with Brazil and U.S.
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
COVAXX Synthetic Multitope Vaccine Selected for Human Trials in Brazil by Dasa, the Largest Diagnostic Company, and Mafra the Leading Private Vaccine Distributor
Dasa, the largest diagnostic medicine company in Brazil and Latin America, and COVAXX, the subsidiary of United Biomedical Inc, a recognized leader in antibody diagnostics and vaccine development, announced today that they have signed a letter of intent to work together to conduct a large scale human efficacy clinical trial in Brazil to develop a vaccine against COVID-19.